Reductions in all-cause and cause-specific mortality among HIV-infected individuals receiving antiretroviral therapy in British Columbia, Canada: 2001–2012

HIV Medicine

Volumn 17, Issue 9, 2016, Pages 694-701

  Cheung, C C ^a   Ding, E ^b   Sereda, P ^b   Yip, B ^b   Lourenco, L ^b   Barrios, R ^b,d   Montaner, J S G ^a,b   Hogg, R S ^b,c   Lima, V ^a,b   Moore, D M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

^d VANCOUVER COASTAL HEALTH   (Canada)

Author keywords

AIDS; antiretroviral therapy; cardiovascular; HIV; liver; mortality; suicide

Indexed keywords

ANTIVIRUS AGENT; ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CHRONIC LIVER DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; DRUG USE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INJURY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; MORTALITY RATE; PARASITOSIS; PRIORITY JOURNAL; SUICIDE; ADOLESCENT; BRITISH COLUMBIA; COHORT ANALYSIS; EPIDEMIOLOGY; FOLLOW UP; HIV INFECTIONS; INCIDENCE; MIDDLE AGED; SURVIVAL ANALYSIS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; BRITISH COLUMBIA; CAUSE OF DEATH; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84973605494     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12379     Document Type: Article

References (22)

1. Lima VD, Lepik KJ, Zhang W, Muldoon KA, Hogg RS, Montaner JS. Regional and temporal changes in HIV-related mortality in British Columbia, 1987-2006. Can J Public Health 2010; 101: 415–419.
2. Antiretroviral Therapy Cohort C. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293–299.
3. Samji H, Cescon A, Hogg RS et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS ONE 2013; 8: e81355.
4. Antiretroviral Therapy Cohort C, Mocroft A, Sterne JA et al. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 2009; 48: 1138–1151.
5. Belvedere LM, Miller CL, Hogg RS. Shifting sands: changing regional and gender-specific patterns of HIV/AIDS mortality in Canada, 1987 to 2008. Can J Public Health 2012; 103: 202–206.
6. Buchacz K, Baker RK, Palella FJ Jr et al. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS 2010; 24: 1549–1559.
7. Mocroft A, Ledergerber B, Katlama C et al. Decline in the AIDS and death rates in the Eurosida study: an observational study. Lancet 2003; 362: 22–29.
8. Hogg RS, Yip B, Chan KJ et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286: 2568–2577.
9. Lima VD, Hogg RS, Harrigan PR et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007; 21: 685–692.
10. Emery S, Neuhaus JA, El-Sadr W et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the smart study. J Infect Dis 2008; 197: 1133–1144.
11. Kitahata MM, Gange SJ, Abraham AG et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 1815–1826.
12. Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the international AIDS society-USA panel. JAMA 2006; 296: 827–843.
13. Hammer SM, Eron JJ Jr, Reiss P et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the international AIDS society-USA panel. JAMA 2008; 300: 555–570.
14. Thompson MA, Aberg JA, Cahn P et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the international AIDS society-USA panel. JAMA 2010; 304: 321–333.
15. Thompson MA, Aberg JA, Hoy JF et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the international antiviral society-USA panel. JAMA 2012; 308: 387–402.
16. Ehren K, Hertenstein C, Kummerle T et al. Causes of death in HIV-infected patients from the cologne-bonn cohort. Infection 2014; 42: 135–140.
17. Montaner JS, Lima VD, Barrios R et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376: 532–539.
18. Patterson S, Cescon A, Samji H et al. Cohort profile: haart observational medical evaluation and research (HOMER) cohort. Int J Epidemiol 2014; 00: 00–00.
19. El-Sadr WM, Lundgren J, Neaton JD et al. CD4 + count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283–2296.
20. Carpenter CC, Cooper DA, Fischl MA et al. Antiretroviral therapy in adults: updated recommendations of the international AIDS society-USA panel. JAMA 2000; 283: 381–390.
21. Joy R, Druyts EF, Brandson EK et al. Impact of neighborhood-level socioeconomic status on HIV disease progression in a universal health care setting. J Acquir Immune Defic Syndr 2008; 47: 500–505.
22. Vital Statistics Agency B.BC Annual Report (2001–2011). 2011; Available athttp://www.vs.gov.bc.ca/stats/annual/